2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| BridgeBio Pharma LLC | — | 14,589,846 | Oct 16, 2025 |
| BridgeBio Pharma LLC | — | 14,589,846 | Oct 16, 2025 |
| Chen Bihua | CEO | 10,124,482 | Aug 13, 2025 |
| Wallace Eli M. | — | 1,614,400 | Oct 6, 2025 |
| Helix Holdings II LLC | — | 509,000 | Feb 13, 2024 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jan 1, 2026 | Jan 5, 2026 | Wallace Eli M. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 10, 2025 | Dec 12, 2025 | Wallace Eli M. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 10, 2025 | Oct 16, 2025 | BridgeBio Pharma LLC | 10% Owner | Neutral | 85.0 | +784,720 | 5.68% | ✗ | - |
| Oct 2, 2025 | Oct 6, 2025 | Wallace Eli M. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 28, 2025 | Tipirneni Praveen P. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 28, 2025 | MCCORMICK FRANK | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 28, 2025 | Bauer Jake | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 28, 2025 | Beltran Pedro | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 28, 2025 | Ben Yong | Chief Med & Dev Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 28, 2025 | Wallace Eli M. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 26, 2025 | Aug 28, 2025 | Mehra Uneek | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 18, 2025 | Tipirneni Praveen P. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | DOIG MICHELLE | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | MCCORMICK FRANK | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | BridgeBio Pharma LLC | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | Bauer Jake | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | Kumar Neil | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | Ben Yong | Chief Med & Dev Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | Wallace Eli M. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | Mehra Uneek | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 18, 2025 | Beltran Pedro | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 11, 2025 | Aug 13, 2025 | Chen Bihua | Director | Neutral | 90.0 | +10,797,468 | 152.48% | ✗ | - |
| Aug 11, 2025 | Kelleher Raymond J. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 11, 2025 | Obradovic Nebojsa | Chief Legal Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 11, 2025 | Tripp Caleb | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 11, 2025 | Aug 11, 2025 | Holman Albert A III | Other | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 11, 2025 | Aug 11, 2025 | McKenna Mark C. | Other | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 11, 2025 | Aug 11, 2025 | Schmid John P. | Other | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Holman Albert A III | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 8, 2025 | Feb 10, 2025 | Helix Holdings II LLC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 8, 2025 | Feb 10, 2025 | Chen Bihua | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 13, 2024 | Feb 13, 2024 | Chen Bihua | CEO | Buy | 100.0 | +2,909,000 | 100.00% | ✗ | $24M |
| Feb 13, 2024 | Feb 13, 2024 | Helix Holdings II LLC | Director | Neutral | 90.0 | +509,000 | 100.00% | ✗ | - |
| Feb 9, 2024 | Schmid John P. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 9, 2024 | Tripp Caleb | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 9, 2024 | Chen Bihua | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 8, 2024 | Obradovic Nebojsa | Chief Legal Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 8, 2024 | Helix Holdings II LLC | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 8, 2024 | McKenna Mark C. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |